What is the debt of OncoCyte this year?
OncoCyte has a debt level of -9.43 USD this year.
OncoCyte Debt 2024
OncoCyte Debt
-9.43 USD
Ticker
OCX
ISIN
US68235C1071
WKN
A2ACBH
In 2024, OncoCyte's total debt was -9.43 USD, a -52.6% change from the -19.9 USD total debt recorded in the previous year.
OncoCyte Aktienanalyse
What does OncoCyte do?
OncoCyte Corp is a company based in Alameda, California, that is involved in the field of cancer diagnostics. It was founded in 2009 with the goal of developing and commercializing innovative solutions for cancer diagnosis. The business model of OncoCyte Corp is based on the development and marketing of diagnostic tests for various types of cancer. The company focuses on identifying biomarkers that enable accurate and reliable diagnosis. The tests developed by OncoCyte Corp can be used for both early detection and monitoring of cancer patients. OncoCyte Corp is divided into several divisions, each specialized in developing products for specific types of cancer. These divisions include breast cancer, lung cancer, bladder cancer, and ovarian cancer. Each division is led by an expert team with extensive knowledge and experience in the respective area. One of the key products of OncoCyte Corp is the DetermaRx™ test, specifically developed for lung cancer. This test identifies specific biomarkers that provide a prognosis regarding the response to chemotherapy. The DetermaRx™ test is currently in clinical trials and could be used in the future to aid in the decision-making process for selecting the appropriate treatment method for lung cancer patients. Another product of OncoCyte Corp is the DetermaDx™ test, specifically developed for the early detection of breast cancer. This test utilizes a combination of biomarker-based tests and imaging techniques to detect cancer cells at an early stage. The DetermaDx™ test is currently undergoing validation and could potentially become a standard diagnosis for breast cancer in the future. OncoCyte Corp has also formed several partnerships with pharmaceutical and diagnostic companies to promote the development and commercialization of its products. One such partnership exists with Life Technologies Corporation, a globally leading company in the field of diagnostics and analytics. OncoCyte Corp strives to develop and bring to market innovative solutions for cancer diagnosis. With its vast resources and experienced team of scientists, the company has the potential to change the way cancer is diagnosed and treated. OncoCyte ist eines der beliebtesten Unternehmen auf Eulerpool.com.Debt Details
Understanding OncoCyte's Debt Structure
OncoCyte's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.
Year-to-Year Comparison
Analyzing OncoCyte's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.
Impact on Investments
Investors pay close attention to OncoCyte’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.
Interpreting Debt Fluctuations
Shifts in OncoCyte’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.
Frequently Asked Questions about OncoCyte stock
What was the debt of OncoCyte compared to the previous year?
The debt of OncoCyte has increased by -52.6% compared to the previous year dropped.
What are the consequences of high debt for investors in OncoCyte?
High debt can pose a risk for investors of OncoCyte, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.
What are the consequences of low debt for investors of OncoCyte?
Low debt means that OncoCyte has a strong financial position and is able to fulfill its obligations without overburdening its finances.
How does an increase in debt from OncoCyte affect the company?
An increase in debt of OncoCyte can adversely affect the financial condition of the company and result in a higher burden on its finances.
How does a reduction of debt of OncoCyte affect the company?
A reduction in debt of OncoCyte can strengthen the company's financial position and improve its ability to meet its financial obligations.
What are some factors that influence the debt of OncoCyte?
Some factors that can influence the debt of OncoCyte include investments, acquisitions, operating costs, and revenue development.
Why are the debts of OncoCyte so important for investors?
The debts of OncoCyte are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.
What strategic measures can OncoCyte take to change the debt?
To change the debt, OncoCyte can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.
How much dividend does OncoCyte pay?
Over the past 12 months, OncoCyte paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, OncoCyte is expected to pay a dividend of 0 USD.
What is the dividend yield of OncoCyte?
The current dividend yield of OncoCyte is .
When does OncoCyte pay dividends?
OncoCyte pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of OncoCyte?
OncoCyte paid dividends every year for the past 0 years.
What is the dividend of OncoCyte?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is OncoCyte located?
OncoCyte is assigned to the 'Health' sector.
Wann musste ich die Aktien von OncoCyte kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of OncoCyte from 9/26/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/26/2024.
When did OncoCyte pay the last dividend?
The last dividend was paid out on 9/26/2024.
What was the dividend of OncoCyte in the year 2023?
In the year 2023, OncoCyte distributed 0 USD as dividends.
In which currency does OncoCyte pay out the dividend?
The dividends of OncoCyte are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von OncoCyte
Our stock analysis for OncoCyte Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of OncoCyte Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
